Less than one month after NuPathe’s (Nasdaq: PATH) board approved an acquisition offer by Endo Health Solutions, (Nasdaq: ENDP) the specialty pharmaceutical company has unexpectedly found itself at the center of what could be a bidding war after receiving another offer in a surprising development in life science industry news. Big pharma company Teva (NYSE: […]
The leadership change at NuPathe (NASDAQ:PATH) has ushered in a CEO with the sales and marketing background to bring its first product — a migraine patch — to market, a move that is likely to loosen up the purse strings of conservative investors. Tracy T. Lefteroff, managing partner of the venture capital practice at PricewaterhouseCoopers, […]
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Biopharmaceutical firm NuPathe’s (NASDAQ:PATH) CEO Jane Hollingsworth has resigned as CEO and board member of the company she co-founded more than six years ago. She has been replaced by the former CEO of Auxilium Pharmaceuticals (NASDAQ:AUXL), another company Hollingsworth co-founded. The move comes as NuPathe gears up to commercialize its lead product the Zelrix […]
NuPathe (NASDAQ:PATH), a biopharmaceutical company, has resubmitted a new drug application for its migraine patch to the U.S. Food and Drug Administration after resolving issues raised in a complete response letter last year. The Zelrix transdermal patch is designed to transmit sumatriptan via electrical charge through the skin in a drug-delivery method known as iontophoresis. […]
NuPathe (NASDAQ: PATH) said it will resubmit a new drug application for its transdermal migraine patch for approval by the U.S. Food and Drug Administration after receiving a complete response letter from the regulator, according to the company’s third quarter earnings report. NuPathe said the issues raised in the August 29 letter from the FDA […]
Highlights of the important and the interesting from the world of healthcare: Has the iPad been a disappointment for healthcare? Doubt any promise you hear about the iPad having a huge impact on the way healthcare is delivered–at least for now, writes Sandra Yin. Some of the breathless articles fawning over the device have overyped […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Highlights of the important and the interesting from the world of healthcare: Return of the public option? Don’t bet on it: Nearly 130 House Democrats are pushing to restore the once-proposed “public option“–essentially a government-run health plan. Fueling the drive is a report from the Congressional Budget Office that said a public option would shave […]